RNAi-Based Therapeutics Summit on January 28-30, 2025 in Boston, United States

As innovative drug delivery platforms beyond GalNac continue to emerge and novel chemical modifications are discovered, the potential for RNAi therapeutics to treat a plethora of diseases grows. Now more than ever, RNAi therapies hold promise to treat diseases beyond the liver and provide efficacious, tolerable treatment options for patients.

The 6th RNAi-Based Therapeutics Summit is returning to Boston to showcase the latest delivery technologies, data from clinically successful extra-hepatic targeting, cutting-edge AI tools to assist payload design, and breakthrough chemical modifications which enhance stability, allowing for precise therapeutic delivery.

Uniting 70+ leaders of the RNAi world, this Summit will empower experts to pioneer their RNAi candidates into clinically successful therapies. Bringing together technical and strategic experts from Novo Nordisk, Alynlam, Switch Therapeutics, Aro Biotherapeutics, Novartis, Comanche Biopharma and more, this meeting is a unique gathering of RNAi's sharpest minds, dedicated to progressing the next wave of RNAi therapeutics to improve healthcare for patients in need.

URLs:
Tickets: https://go.evvnt.com/2676365-2?pid=10008
Brochure: https://go.evvnt.com/2676365-3?pid=10008

Time: 8:00 AM - 6:00 PM

Prices:

Conference + Workshop Day - Drug Developer Pricing: USD 4197.00,

Conference Only - Drug Developer Pricing: USD 2999.00,

Conference + Workshop Day - Academic Pricing: USD 3597.00,

Conference Only - Academic Pricing: USD 2599.00,

Conference + Workshop Day - Solution Provider Pricing: USD 5097.00,

Conference Only - Solution Provider Pricing: USD 3699.00

Speakers: Adam Dinerman, Senior Vice President and Head of Chemistry, Manufacturing and Controls, Aro Biotherapeutics , Ali Shah, Co-Founder and Chief Executive Officer, Tallas Biotech, Andrew Fraley, Partner, Sunrise Bioventures, Ashling Holland, Director of Research and Preclinical Development, PepGen, Benjamin Kreitman, Principal, Broadview Ventures, Chad Miller, Head of Research, Nosis Biosciences, David Jackson, Chief Executive Officer, Ceria Therapeutics, David Sharp, Chief Executive Officer, Microcures, Eriks Rozners, Professor, Binghamton University Research Foundation, Glenn Kazo, Chief Business Officer, ARIZ Precision Medicines, Hanhua Huang, Vice President, Biology, Avidity Biosciences, Hunghao Chu, Associate Director, Benitec Ltd, Jingfang Ju, Professor, Stony Brook University, Julia Alterman, Assistant Professor, University of Massachusetts Medical School, Lucas Siow, Chief Executive Officer and Co-Founder, ProteinQure, Mohammad Shadid, Vice President - Preclinical Development, Korro Bio, Ruben Postel, Chief Scientific Officer and Scientific Founder, Sapreme Technologies, Scott Harper, Co-founder, Armatus Bio and Principal Investigator, Nationwide Children's Hospital, Shanthi Ganesh, Director - Global Nucleic Acid Therapies, Novo Nordisk, Shilpi Mahajan, Associate Director and Head of Bioanalytics, Switch Therapeutics, Vignesh Narayan Hariharan, Director of Biology, Comanche Biopharma and Instructor, University of Massachusetts Medical School, Weimin Wang, Founder and Chief Executive Officer, SanegeneBio, Yuanyuan Jin, Co-founder and Chief Operating Officer, Bound Therapeutics, Zdravka Medarova, Chief Scientific Officer, TransCode Therapeutics, Zhanna Druzina, Senior Director, Aro Biotherapeutics, Zhihong Huang, Associate Director, Global Discovery Chemistry, Novartis AG